Metraipolis › archive › dc_ae8bd4660144
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab — Europe PMC PMID:41560729
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41560729
- DOI
- 10.3389/fphar.2025.1714173
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T01:47:03.469Z
- SHA-256 of the archived text
da8ea89d48e66a12d63632c2059140c566580b78b7dfe2b6426349d30dd89a68- Stable URL of this page
https://metraipolis.com/documento/dc_ae8bd4660144
How to cite
A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab — Europe PMC PMID:41560729 — Europe PMC (en), https://europepmc.org/article/MED/41560729 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ae8bd4660144 (Metraipolis archive dc_ae8bd4660144, sha256 da8ea89d48e66a12d63632c2059140c566580b78b7dfe2b6426349d30dd89a68)
BibTeX
@misc{dcae8bd4660144,
title = {A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for bimekizumab — Europe PMC PMID:41560729},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41560729},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ae8bd4660144; sha256 da8ea89d48e66a12d63632c2059140c566580b78b7dfe2b6426349d30dd89a68},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41560729. Agents can read the archived copy with the MCP tool read_document.